fashion -WSS

fashion

author：comprehensive 2025-08-12 09:12:23 - browse：6655

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： House transparency, PBM reform bill gains bipartisan support

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

Syphilis numbers in the United States reach record heights

'Make People Better': The CRISPR babies story you probably don't know

ALS advocates say criticism of new drugs misses bigger picture

Listen: Biogen's potential pivot, & Illumina's next chapter

White House pharmacy plagued with problems, investigation finds

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Advances in CAR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Reconstructing family trees of blood cells may help predict disease

Anesthesiologist group: stop taking Ozempic before surgery

How generative AI is inspiring dreams of a health data revolution

23andMe had bad news about my health. I wish a person had delivered it

Medicare drug price negotiation legal challenge met with skepticism

Continuity nursing helped my family in our darkest PICU moments

Biogen walks away from Aduhelm, years after polarizing approval

hotspot

Amazon on where the company's health care bets are headed next

NIH nominee Bertagnolli will get October confirmation hearing

Biogen walks away from Aduhelm, years after polarizing approval

The (many) problems with a new study criticizing cancer screening

A rare thyroid diagnosis led to unexpected, all

Humana’s losses in Medicare Advantage tank its stock

hotspot

hotspot

knowledge

Wikipedia